SOX2 and neoplasm: The cancer patients with elevated SOX2-OT expression were more likely to have advanced clinical stage (RR = 1.468, 95% CI: 1.106-1.949, <i>P</i> = 0.0079), earlier lymphatic metastasis (<i>P</i> = 0.0005), earlier distant metastasis (<i>P</i> < 0.0001), greater tumor size (<i>P</i> < 0.0001), and more extreme tumor invasion (<i>P</i> < 0.0001) compared to those with low SOX2-OT expression.